The GMO Panel has previously assessed GM soybean BPS‐CV127‐9 and found it to be as safe and nutritious as its conventional counterpart and commercial soybean varieties with respect to potential effects on human and animal health and the environment in the context of its intended uses. EFSA was requested by the European Commission to analyze new nucleic acid sequencing data and updated bioinformatics data for GM soybean BPS‐CV127‐9 and to indicate whether the previous conclusions of the GMO Panel on safety of GM soybean BPS‐CV127‐9 remain valid.
According to EFSA, with the exception of bioinformatics analyses, the studies performed for the risk assessment of the single event soybean BPS‐CV127‐9 remain valid. The new sequencing data and the bioinformatics analyses performed on the new sequence did not give rise to safety issues. Therefore, EFSA concludes that the original risk assessment of soybean BPS‐CV127‐9 remains valid.
For more details, read the risk assessment available in the EFSA Journal.